CL2018001434A1 - Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona - Google Patents

Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Info

Publication number
CL2018001434A1
CL2018001434A1 CL2018001434A CL2018001434A CL2018001434A1 CL 2018001434 A1 CL2018001434 A1 CL 2018001434A1 CL 2018001434 A CL2018001434 A CL 2018001434A CL 2018001434 A CL2018001434 A CL 2018001434A CL 2018001434 A1 CL2018001434 A1 CL 2018001434A1
Authority
CL
Chile
Prior art keywords
quinazolin
piperidin
oxo
amino
methyl
Prior art date
Application number
CL2018001434A
Other languages
English (en)
Inventor
Michael Pourdehnad
Anita Gandhi
Patrick Hagner
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2018001434A1 publication Critical patent/CL2018001434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN LA PRESENTE SE PROPORCIONAN MÉTODOS PARA TRATAR, PREVENIR Y/O CONTROLAR EL CÁNCER, INCLUSIVE LINFOMA, QUE COMPRENDEN LA ADMINISTRACIÓN A UN PACIENTE DE 3-(5-AMINO-2-METIL-4-OXO-4H-QUINAZOLIN-3-IL)-PIPERIDIN-2,6-DIONA, O UN ENANTIÓMERO O UNA MEZCLA DE ENANTIÓMEROS DE ESTE, O UNA SAL, SOLVATO, HIDRATO, COCRISTAL, CLATRATO O POLIMORFO DE ESTOS FARMACÉUTICAMENTE ACEPTABLES EN UNA PAUTA DE TERAPIA CÍCLICA.
CL2018001434A 2015-12-02 2018-05-29 Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona CL2018001434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562262263P 2015-12-02 2015-12-02

Publications (1)

Publication Number Publication Date
CL2018001434A1 true CL2018001434A1 (es) 2018-08-31

Family

ID=57614460

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001434A CL2018001434A1 (es) 2015-12-02 2018-05-29 Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Country Status (13)

Country Link
US (1) US10159675B2 (es)
EP (1) EP3383398A1 (es)
JP (1) JP2018535992A (es)
KR (1) KR20180088401A (es)
AU (1) AU2016364753A1 (es)
BR (1) BR112018010964A2 (es)
CA (1) CA3006758A1 (es)
CL (1) CL2018001434A1 (es)
EA (1) EA201891289A1 (es)
IL (1) IL259597A (es)
MX (1) MX2018006779A (es)
SG (1) SG11201804367PA (es)
WO (1) WO2017096024A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
WO2018165142A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2024108028A1 (en) * 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
GB0205395D0 (en) * 2002-03-07 2002-04-24 Univ Southampton Materials and methods relating to the treatment of lymphoma
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
JP5959543B2 (ja) 2011-03-11 2016-08-02 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用
AU2012229300B2 (en) 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
ES2872967T3 (es) * 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
WO2016007854A1 (en) * 2014-07-11 2016-01-14 Celgene Corporation Combination therapy for cancer
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
WO2017035443A1 (en) 2015-08-27 2017-03-02 Celgene Corporation Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
IL259597A (en) 2018-07-31
US20170157123A1 (en) 2017-06-08
JP2018535992A (ja) 2018-12-06
SG11201804367PA (en) 2018-06-28
AU2016364753A1 (en) 2018-06-14
KR20180088401A (ko) 2018-08-03
CA3006758A1 (en) 2017-06-08
MX2018006779A (es) 2018-08-01
US10159675B2 (en) 2018-12-25
EA201891289A1 (ru) 2018-11-30
BR112018010964A2 (pt) 2018-12-04
EP3383398A1 (en) 2018-10-10
WO2017096024A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
PH12017500933A1 (en) Sublingual administration of riluzole
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX382754B (es) Terapias combinadas para tratar el cancer.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2017010577A (es) Dosis de panobinostat para el mieloma multiple.
UA100460U (uk) Застосування препарату ноофен як засобу лікування еректильної дисфункції в моно- або комплексній терапії
UA97449U (ru) Способ лечения урогенитальных инфекций у больных артропатическим псориазом
RU2014150855A (ru) Способ лечения сексуальной дисфункции у пациентов с хроническим простатитом